

## Medical Policy:

### High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators

POLICY NUMBER	LAST REVIEW
MG.MM.DM.09cC3v2	September 9, 2022

**Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.**

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

## Definition

A high frequency chest wall oscillation device (HFCWOD) is an airway clearance device consisting of an inflatable vest connected by tubes to a small air-pulse generator.

## Guideline

Members are eligible for coverage of an HFCWOD when any of the following conditions/diagnoses are applicable:

1. Acid maltase deficiency
2. Amyotrophic lateral sclerosis
3. Anterior horn cell diseases
4. Bronchiectasis
5. Cystic fibrosis
6. Hereditary muscular dystrophy
7. Multiple sclerosis
8. Myotonic disorders
9. Other myopathies

10. Paralysis of the diaphragm
11. Post-polio
12. Quadriplegia
13. Any neuromuscular disease disorder with ineffective cough
14. Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed

Well-documented failure of standard treatments to adequately mobilize retained secretions must be made available to the Plan upon request.

## Limitations/Exclusions

High frequency chest wall oscillation devices are not covered for any conditions other than those listed above. Intrapulmonary percussive ventilators (IPV) (e.g., the Impulsator F00012) are considered experimental and investigational for all indications due to insufficient evidence of therapeutic value (including but not limited to bronchiectasis, chronic obstructive pulmonary disease [COPD], cystic fibrosis, neuromuscular conditions associated with retained airway secretions or atelectasis, and post-operative pulmonary complications).

## Procedure Codes

A7025	High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each
E0467	Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions
E0483	<del>High frequency chest wall oscillation air pulse generator system, (includes hoses and vest), each</del> High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each (Revised: 10/1/2022)

## Diagnosis Codes

A15.0	Tuberculosis of lung
B91	Sequelae of poliomyelitis
D81.810	Biotinidase deficiency
D84.1	Defects in the complement system
E84.0	Cystic fibrosis with pulmonary manifestations
E84.11	Meconium ileus in cystic fibrosis
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
G12.1	Other inherited spinal muscular atrophy
G12.20	Motor neuron disease, unspecified
G12.21	Amyotrophic lateral sclerosis

G12.22	Progressive bulbar palsy
G12.23	Primary lateral sclerosis
G12.24	Familial motor neuron disease
G12.25	Progressive spinal muscle atrophy
G12.29	Other motor neuron disease
G12.8	Other spinal muscular atrophies and related syndromes
G12.9	Spinal muscular atrophy, unspecified
G14	Postpolio syndrome
G35	Multiple sclerosis
G71.00	Muscular dystrophy, unspecified
G71.01	Duchenne or Becker muscular dystrophy
G71.02	Facioscapulohumeral muscular dystrophy
G71.09	Other specified muscular dystrophies
G71.11	Myotonic muscular dystrophy
G71.12	Myotonia congenita
G71.13	Myotonic chondrodystrophy
G71.14	Drug induced myotonia
G71.19	Other specified myotonic disorders
G71.20	Congenital myopathy, unspecified
G71.21	Nemaline myopathy
G71.220	X-linked myotubular myopathy
G71.228	Other centronuclear myopathy
G71.29	Other congenital myopathy
G71.3	Mitochondrial myopathy, not elsewhere classified
G71.8	Other primary disorders of muscles
G72.0	Drug-induced myopathy
G72.1	Alcoholic myopathy
G72.2	Myopathy due to other toxic agents
G72.89	Other specified myopathies
G73.7	Myopathy in diseases classified elsewhere
G82.50	Quadriplegia, unspecified
G82.51	Quadriplegia, C1-C4 complete
G82.52	Quadriplegia, C1-C4 incomplete
G82.53	Quadriplegia, C5-C7 complete
G82.54	Quadriplegia, C5-C7 incomplete
J47.0	Bronchiectasis with acute lower respiratory infection

J47.1	Bronchiectasis with (acute) exacerbation
J47.9	Bronchiectasis, uncomplicated
J98.6	Disorders of diaphragm
M33.02	Juvenile dermatomyositis with myopathy
M33.12	Other dermatomyositis with myopathy
M33.22	Polymyositis with myopathy
M33.92	Dermatopolymyositis, unspecified with myopathy
M34.82	Systemic sclerosis with myopathy
M35.03	Sicca syndrome with myopathy
Q33.4	Congenital bronchiectasis

## References

Centers for Medicare and Medicaid Services. National Coverage Determination for Intrapulmonary Percussive Ventilator. July 1997. Available at: [http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=229&ncdver=1&DocID=240.5&ncd\\_id=240.5&ncd\\_version=1&basket=ncd%25253A240%25252E5%25253A1%25253AIntrapulmonary+Percussive+Ventilator+%252528IPV%252529&bc=gAAAAAgAAAA&](http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=229&ncdver=1&DocID=240.5&ncd_id=240.5&ncd_version=1&basket=ncd%25253A240%25252E5%25253A1%25253AIntrapulmonary+Percussive+Ventilator+%252528IPV%252529&bc=gAAAAAgAAAA&). Accessed September 16, 2022.

Deakins K, Chatburn RL. A comparison of intrapulmonary percussive ventilation and conventional chest physiotherapy for the treatment of atelectasis in the pediatric patient. *Respir Care*. 2002; 47(10):1162-1167.

Irwin RS, Baumann MH, Bolser DC, et al.; American College of Chest Physicians (ACCP). Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. *Chest*. 2006; 129(1 Suppl):1S-23S.

Noridian. LCD for High Frequency Chest Wall Oscillation Devices. January 2020. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33785&ver=34&keywordtype=starts&keyword=high%20frequenc&bc=0>. Accessed September 16, 2022.

Specialty-matched clinical peer review.

Varekojis SM, Douce FH, Flucke RL, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. *Respir Care*. 2003; 48(1):24-28.

## Revision History

Company(ies)	DATE	REVISION
EmblemHealth ConnectiCare	Sept. 13, 2019	Added the following covered indications to HFDWOD: <ul style="list-style-type: none"> <li>- Any neuromuscular disease disorder with ineffective cough</li> <li>- Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed</li> </ul>
ConnectiCare	Jun. 14, 2019	ConnectiCare adopts the clinical criteria of its parent corporation EmblemHealth
EmblemHealth	Jun. 10, 2016	Communicated noncoverage of IPVs